These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 31637485)

  • 1. Hypomethylating agents for patients with myelodysplastic syndromes prior to hematopoietic stem cell transplantation: a systematic review and meta-analysis.
    Qin Y; Kuang P; Zeng Q; Wu Y; Liu T
    Ann Hematol; 2019 Nov; 98(11):2523-2531. PubMed ID: 31637485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of the benefit of hypomethylating agents before allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes.
    Liu L; Jia M; Sun L; Tian W; Tang P; Jiang Z
    Clin Exp Med; 2021 Nov; 21(4):537-543. PubMed ID: 33866494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes.
    Finelli C; Follo MY; Stanzani M; Parisi S; Clissa C; Mongiorgi S; Barraco M; Cocco L
    Curr Pharm Des; 2016; 22(16):2349-57. PubMed ID: 26960675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
    Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose regimens of hypomethylating agents promote transfusion independence in IPSS lower-risk myelodysplastic syndromes: a meta-analysis of prospective studies.
    Wan Z; Han B
    Aging (Albany NY); 2021 Mar; 13(8):11120-11134. PubMed ID: 33818418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
    Flotho C; Sommer S; Lübbert M
    Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical update on hypomethylating agents.
    Duchmann M; Itzykson R
    Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
    Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
    Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The euphoria of hypomethylating agents in MDS and AML: is it justified?
    Sekeres MA
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation.
    Oran B; Kongtim P; Popat U; de Lima M; Jabbour E; Lu X; Chen J; Rondon G; Kebriaei P; Ahmed S; Andersson B; Alousi A; Ciurea S; Shpall E; Champlin RE
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1618-25. PubMed ID: 24953017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-transplant hypomethylating agents do not influence post-transplant survival in myelodysplastic syndrome.
    Modi D; Kim S; Singh V; Ayash L; Alavi A; Ratanatharathorn V; Uberti JP; Deol A
    Leuk Lymphoma; 2019 Nov; 60(11):2762-2770. PubMed ID: 31010370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research.
    Potter VT; Iacobelli S; van Biezen A; Maertens J; Bourhis JH; Passweg JR; Yakhoub-Agha I; Tabrizi R; Bay JO; Chevallier P; Chalandon Y; Huynh A; Cahn JY; Ljungman P; Craddock C; Lenhoff S; Russell NH; Fegueux N; Socié G; Bruno B; Meijer E; Mufti GJ; de Witte T; Robin M; Kröger N
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1615-1620. PubMed ID: 27264633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
    Xie M; Jiang Q; Xie Y
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):22-8. PubMed ID: 25042977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic Syndromes.
    Komrokji RS
    Am Soc Clin Oncol Educ Book; 2016; 35():e345-52. PubMed ID: 27249741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome.
    Apuri S; Al Ali N; Padron E; Lancet JE; List AF; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):211-214. PubMed ID: 28185797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes.
    Wang R; Gross CP; Maggiore RJ; Halene S; Soulos PR; Raza A; Galili N; Ma X
    Leuk Res; 2011 Jul; 35(7):904-8. PubMed ID: 21067809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
    Lübbert M; Ihorst G; Sander PN; Bogatyreva L; Becker H; Wijermans PW; Suciu S; Bissé E; Claus R
    Br J Haematol; 2017 Feb; 176(4):609-617. PubMed ID: 27905102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in the DNA methylation pathway predict clinical efficacy to hypomethylating agents in myelodysplastic syndromes: a meta-analysis.
    Du M; Zhou F; Jin R; Hu Y; Mei H
    Leuk Res; 2019 May; 80():11-18. PubMed ID: 30884372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study.
    Jabbour E; Mathisen MS; Garcia-Manero G; Champlin R; Popat U; Khouri I; Giralt S; Kadia T; Chen J; Pierce S; Koca E; Daver N; Tanaka M; Rondon G; Oran B; Parmar S; Kantarjian H; de Lima M
    Am J Hematol; 2013 Mar; 88(3):198-200. PubMed ID: 23345254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?
    Steensma DP
    Best Pract Res Clin Haematol; 2012 Dec; 25(4):443-51. PubMed ID: 23200541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.